Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TROP2-CAR-NK
- Development stage
- Phase 2
- Lead developer
- Bellicum Pharmaceuticals
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TROP2-CAR-NK is an investigational cell therapy consisting of natural killer (NK) cells engineered with a chimeric antigen receptor (CAR) targeting the tumor-associated calcium signal transducer 2 (Trop-2) protein. Trop-2 is overexpressed in various solid tumors and plays a role in tumor growth, invasion, and metastasis. By engineering NK cells to express a CAR specific for Trop-2, these modified immune cells can recognize and kill Trop-2–positive tumor cells that may evade normal immune detection. The therapy is being studied both as monotherapy and in combination with other agents such as cetuximab for the treatment of advanced solid tumors, including colorectal cancer, HER2-negative breast cancer, high-grade serous ovarian cancer, and other locally advanced malignant neoplasms[1][4][5][8]. The primary developer identified is Bellicum Pharmaceuticals.
- Other names
- TROP2-CAR-NK cellsTROP-2-CAR-NK cellsTROP 2-CAR-NK cells
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on TROP2-CAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TROP2-CAR-NK.